Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
In a clinical trial, nearly 60% of participants achieved remission and 41% fully tapered off oral corticosteroids.
AstraZeneca's Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic ...
Medpage Today on MSN3d
FDA OKs New Option for Rare Immune-Mediated VasculitisThe FDA approved the asthma drug benralizumab (Fasenra) as a new therapy for adults with eosinophilic granulomatosis with ...
The randomized, double-blind, placebo-controlled phase 3 MATINEE study evaluated the safety and efficacy of mepolizumab in patients with COPD and type 2 inflammation.
Adding GSK’s mepolizumab to standard inhaled treatment for COPD reduces the frequency of exacerbations in patients with type ...
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...
More than half (60%) of patients in latest trial reached active remission and 41% stopped taking corticosteroid entirely.
AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of ...
AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the ...
AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).1 EGPA is a rare, immune-mediated ...
The FDA has approved Fasenra® (benralizumab) for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback